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Abstract: Muscle invasive urinary bladder cancer is one of the most 
lethal cancers and its detection at the time of transurethral resection 
remains limited and diagnostic methods are urgently needed. We have 
developed a muscle invasive transitional cell carcinoma (TCC) model 
of the bladder using porcine bladder scaffold and the human bladder 
cancer cell line 5637. The progression of implanted cancer cells to 
muscle invasion can be monitored by measuring changes in the 
spectrum of endogenous fluorophores such as reduced nicotinamide 
dinucleotide (NADH) and flavins. We believe this could act as a useful 
tool for the study of fluorescence dynamics of developing muscle 
invasive bladder cancer in patients. 
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1. Introduction 
Carcinoma of the urinary bladder is one of the most common urological cancers (4th most 
frequent malignant disease in men and 7th most frequent in women). In 75–85% of these 
the cancer does not infiltrate into deeper muscle, i.e. it is carcinoma in situ (CIS), stage 
Ta/T1 (non-invasive) on first diagnosis; 50–70% of these patients presenting with 
superficial (non-muscle invasive) stages have one or several recurrences after the initial 
treatment, and in ≈15% there is disease progression [1]. Sensitivity and specificity of 
current cystoscopy and urinary biomarkers including cytology are far from satisfactory, 
leading to use of invasive cystoscopy as a follow-up investigation. The high rates of 
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recurrence in non-muscle invasive urinary bladder cancer and its progression make it one 
of the most expensive cancers to treat on a per patient basis [2–4]. One of the major 
developments in increased sensitivity diagnosis of bladder cancer was the advent of 
photodynamic diagnosis (PDD) using photosensitizers (PS), including 5-aminolaevulinic 
acid. Unfortunately, PS agents are also retained and converted preferentially by inflamed 
or infected tissue, reducing diagnostic specificity. Therefore, PDD causes many more 
false positives than white light cystoscopy (WLC), leading to increased biopsy turnover 
and increased patient morbidity [5,6]. It is clear that something must be done to balance 
this. 
In recent years, endogenous fluorescence spectroscopy has been gaining attention as a 
means to diagnose and monitor bladder cancer with improved sensitivity without 
compromising on specificity. The technique is based upon the excitation of particular 
endogenous fluorophores, including collagen, elastin and reduced Nicotinamide 
Dinucleotide (NADH) [7], which can give a wealth of structural and metabolic 
information about tissue [8]. Many recent studies have demonstrated the diagnostic worth 
of endogenous fluorescence spectroscopy in several cancers [9], including bladder cancer 
[10], however this information is often conflicting. Endogenous fluorescence 
spectroscopy has demonstrated the ability to discriminate and quantify tissue and cellular 
levels of fluorophores [11], and the calculation of ratios including the optical redox ratio 
[12–14] of tissues can provide complex information on how cellular systems progress. 
Clinical diagnostic implementation of endogenous fluorescence spectroscopy relies on 
consensus being reached regarding diagnostically relevant fluorophores and their 
dynamics in healthy and cancerous tissue. Furthermore, systems allowing us to monitor 
fluorescence changes in tissue as it progresses from healthy to CIS to non-muscle 
invasive bladder cancer (NMIBC) and finally to invasive cancer could inform grading 
and staging and help to improve disease monitoring and follow-up. 
We have developed an in vitro organoid model of invasive bladder cancer following 
previous work by Southgate et al. [15] to allow us to monitor fluorescence dynamics in 
the lab using a minimally invasive spectroscopic probe. Organoids are becoming widely 
used tissue mimics in labs worldwide as they allow the exploration of minute cell and 
tissue details in close to lifelike conditions. Organoids have previously been developed 
for many tissue types, ranging from colon [16] to prostate [17], and utilise tissue from 
many animal types, including rat, pig and human explants. Previous work in the field of 
bladder organoids has established spheroids [18], reliable, small scale mucosal models 
from rats [19] and full tissue models from porcine bladder, mostly concerned with tissue 
mimics for drug development [20] and disease recurrence [21] and invasion assays. To 
our knowledge, there are no existing studies employing bladder cancer organoids to study 
tissue autofluorescence dynamics, therefore ours represents the first of its kind. We 
hypothesised that tumour organoids developed in this way would express different levels 
of fluorophores from control tissue across the study period – in particular we anticipated 
increased cellular fluorophores such as NADH and flavins as tumour cells adhered and 
formed an epithelial layer on tissue, potentially alongside reduced collagen and elastin 
levels as tumour cells remodelled the surrounding matrix to promote growth and 
invasion. 
The fluorescence data obtained over a 21 day study period display definitive changes 
in several fluorophore ratios, suggestive of progressive cancer cell epithelialisation of 
tissue and destruction of structural proteins to facilitate tissue invasion. 
2. Materials and methods 
2.1 Porcine bladder scaffold 
Porcine bladders from freshly slaughtered pigs were purchased from Medical Meat 
Supplies Ltd. The tissue was halved to reveal the urothelial surface of the bladder. From 
one half of the bladder, a 20 cm2 (4cm x 5cm) section was cut with a scalpel. From this, 
the mucosa and a small section of muscle were cut away from the remaining muscle 
layer, to give a tissue scaffold with a remaining thickness of roughly 2-3mm. The 
mucosa/muscle layer was kept and the remaining muscle was discarded. Following this, 
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the tissue scaffold was cut into 20 identical sections of 1cm2, washed x 3 in Dulbecco’s 
Phosphate Buffered Saline (DPBS) (Sigma Aldrich) to remove leftover urine or 
contaminants, sterilised in 10,000 Units Penicillin- 10mg Streptomycin solution (Sigma 
Aldrich) and transferred to 0.25% Trypsin – ethylenediaminetetraacetic acid (EDTA) 
solution (Sigma Aldrich) and incubated for 15 minutes to disrupt urothelium, following 
which they were again washed in DPBS x 3 and placed in individual wells of a Corning 
Costar 12 well plate (Sigma Aldrich). A cross section of the tissue scaffold (1a) and an 
image of the optical probe in contact with the tissue (1b) are included in Fig. 1. 
 
Fig. 1. Setup of optical probe in relation to tissue scaffold showing (a) a schematic cross-
section of tissue and optical probe (1 = optical probe, 2 = mucosal layer, 3 = connective 
tissue and 4 = muscle layer), and (b) an image of the optical probe in contact with the 
mucosal surface of tissue (1 = optical probe, 2 = mucosal surface of tissue scaffold). 
2.2 Cell culture 
Bladder cancer cell line “5637” was purchased from American Type Culture Collection 
and grown for several passages in Dulbecco’s Modified Eagle Medium (DMEM) (Sigma 
Aldrich) supplemented with 10% Fetal Bovine Serum (FBS) (Sigma Aldrich) and 1% 
Penicillin-Streptomycin (Sigma Aldrich) in 75cm2 cell culture flasks (Corning). At 70% 
confluence, cells from one flask were detached by conventional trypsinisation, 
resuspended in DMEM, split into ten 15ml Falcon tubes (BD Biosciences) and spun at 
1500RPM for 10 minutes to form pellets. Pellets were applied to ten of twenty bladder 
scaffolds, leaving ten scaffolds as a control. The scaffolds and cell pellets were 
resuspended in 1ml DMEM and incubated overnight. 
2.3 Fluorescence spectroscopy 
Fluorescence spectroscopy was performed using a multi-functional laser based non-
invasive diagnostic system “LAKK-M” (SPE“LAZMA” Ltd, Russia). The “LAKK-M” 
system consists of a central functional unit containing the excitation sources for 
fluorescence diagnosis, laser Doppler flowmetry and tissue reflectance oximetry (these 
two methods not used in this study) and emission detector. These are coupled to a fibre 
optic probe of 1mm diameter with a spacing of 0.5mm between the source and detector. 
The system was initiated 30 minutes prior to study then transferred to the cell culture lab. 
Measurements were performed at the same time on all samples in the afternoon of each 
day on days 0, 1, 4, 7, 11, 14, 18 and 21 of study by gently touching, without pressing 
down, the probe of the “LAKK-M” to the exact centre of the mucosal (upward facing) 
surface of tissue each time. On day 0, tissue was measured prior to seeding of cancer cells 
to ensure all tissues displayed similar fluorescence. Fluorescence measurements were 
performed in the dark to prevent interference from background noise. The “LAKK-M” 
system excites and measures fluorescence across 4 excitation channels: UV (365nm); 
blue (450nm); green (532nm); red (633nm) – samples were studied sequentially for each 
wavelength. Amplitudes of fluorescence excited at each wavelength were detected in the 
detector channel of the probe, converted to electronic signals via a charge coupled device 
(CCD) -matrix and recorded as complex spectra using an in-built spectrometer coupled to 
the detector probe. The spectrometer measures intensity across a wavelength range of 
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350-823nm at 0.2nm increments. Spectra recorded from tissue was visualised on an 
accompanying laptop using custom-made software (LDF 3 v3.1.1.403, SPE “LAZMA” 
Ltd, Russia). Full experimental setup of the fluorescence channel of the LAKK-M system 
is presented in Fig. 2 and more information about the technical specifications of the 
LAKK-M system can be found in previous work by Dunaev et al [22]. 
 
Fig. 2. Experimental setup of the fluorescence channel of the “LAKK-M” multi-
functional system (top left). The system is controlled through the attached laptop (top 
left) to activate laser sources (UV; blue; green and red). Excitation light from the chosen 
source is directed in a source fibre through an optical probe to the biological object (in 
this case, organoid). Emitted fluorescence is transmitted through the detection fibre of the 
optical fibre, through optical filters to the CCD matrix, then finally displayed as a 
complex fluorescence spectrum on the custom software (top right). Spectroscopy 
interface displays a peak of back-scattered laser light (first peak) and a complex 
fluorescence spectrum (second peak) alongside recorded fluorescence intensity values for 
each fluorophore. 
2.4 Confirmation of invasion 
A pilot study was run using the steps described, but for two and twelve days, after which 
the samples were fixed in formalin and submitted to the Tayside Tissue Bank, Ninewells 
Hospital, Dundee, for sectioning and staining of tissue slides with Haematoxylin and 
Eosin. Attachment of cancer cells to scaffold in organoids by day two, and T1 transitional 
cell carcinoma phenotype by day 12, were confirmed by an experienced pathologist. 
Slides were imaged at 200x magnification using a Nikon Eclipse E600 microscope. H & 
E stained slides of control (3a), attachment (3b) and invasion (3c) are included below 
(Fig. 3): 
 
Fig. 3. H & E stained slides showing control (a), cancer cell attachment (b) and cancer 
cell invasion (c). 
2.5 Data analysis 
Data was analysed using custom made analysis software LDF 3 v3.1.1.403 (SPE 
“LAZMA” Ltd). The software calculates and records both the amplitude of fluorescence 
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(Af) and coefficient of fluorescent contrast (Kf) at distinct pre-set wavelengths in 
accordance with previously published literature [22–24]. The fluorophores of interest and 
their excitation and emission values were as follows (Table 1): 
Table 1. The most common endogenous fluorophores 
Fluorophore Excitation (nm) Emission (nm) 
Collagen 365 420 
Elastin 365 450 
NADH 365 490 
Flavins 365 550 
Flavins Blue 450 510 
Lipofuscin 532 570 
Carotene 532 608 
Porphyrins 633 710 
Optical redox ratio (a measure of metabolic function) was calculated for each sample 
on each day as NADH (ex365 em490)/Flavin (ex365 em550) and as NADH (ex365 
em490)/Flavin (ex450 em510). Additionally, the following ratios were also calculated: 
Elastin/NADH; NADH/Collagen and Elastin/Flavin. Average and ratio values were 
compared by plotting mean + SEM (Standard Error of the Mean) for control versus 
organoid over the 21 days of study. One control sample was removed from study on day 
4 owing to fungal contamination. Two further control samples were removed on day 18 
due to fungal contamination. Collected data were analysed and plotted as graphs using 
Origin Pro 8 (OriginLab). Data were compared and assessed for statistically significant 
differences at each time point using AOV (ANOVA) test in R Studio (leverage of 
residuals and Q-Q plots were assessed to ensure applicability of analysis) for p value with 
p < 0.05 considered statistically significant. Raw data from fluorescence analysis and 
statistical analysis have been stored on a secure computer for any potential future access. 
3. Results 
3.1 Optical redox ratio 
Optical redox ratio (ORR) values (measured as NADH (ex365em490)/flavins 
(ex365em550)) show a sharp decrease in organoids, from equitable levels to control at 
day 0 to progressive decreases across day 1-21 (Fig. 4). Data at day 0, before addition of 
cancer cells, were found to not be statistically significantly different (p = 0.334), however 
data on each subsequent day were found to be statistically significantly different (p < 
0.05). Day to day variations in environment and instrumentation are accounted for by 
control. ORR calculated using flavins measured under blue excitation (ex450em510) 
showed no significant difference over the course of the experiment (p > 0.05). This could 
be a result of slight movement of the optical probe when switching from UV to blue 
excitation sources. 
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 Fig. 4. Average ORR values across experimental period for control (solid line) and 
organoid (dotted line). Error bars represent standard error of the mean. 
3.2 Elastin relative to metabolic cofactors 
Taking the ratio of elastin fluorescence (ex365em450) against that from both the 
metabolic cofactors NADH (ex365em490) (5a) and flavins (ex365em550) (5b) also 
shows significant decreases in the relative elastin levels compared to these fluorophores 
in organoids across the 21 day period (Fig. 5). For elastin/NADH measurements, data at 
day 0 and day 1 were not statistically significant (p = 0.668 and p = 0.146, respectively), 
however differences in data from each subsequent day was statistically significant (p < 
0.05). Data from elastin/flavin measurements on day 0 were not statistically significant (p 
= 0.598), however differences in data were statistically significant on each subsequent 
day (p < 0.05). Data from NADH/collagen showed no consistent statistically significant 
changes across the experimental period. Furthermore, data for this ratio on day 0 prior to 
addition of cancer cells was statistically significant (p = 0.0182). This is possibly due to 
very low relative fluorescence of collagen recorded at ex365em420 making it susceptible 
to background noise interference. 
 
Fig. 5. Average ratios of Elastin/NADH (a) and Elastin/Flavins (b) across experimental 
period in control (solid line) and organoid samples (dotted line). Error bars represent 
standard error of the mean. 
All data created during this research are openly available from the University of 
Dundee data repository at http://dx.doi.org/10.15132/10000108. 
4. Discussion 
From the data presented in this paper, we can clearly see patterns of fluorescence emerge 
as tissue scaffold is adhered to and invaded by the cancer cells. We have assessed 
fluorescence from distinct endogenous tissue fluorophores using the “LAKK-M” 
diagnostic system and based on analysis techniques previously followed by Dunaev et al. 
[22] and Akbar et al. [23]. Previous studies generating bladder organoids from porcine 
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bladders have demonstrated viability of cells within tissue scaffolds up to 3 weeks after 
induction [25]. From this we concluded that 3 weeks would be a suitable time frame for 
our fluorescence study. Our work has shown that the UV spectrum of organoids changes 
relative to control across the experimental period. To investigate why this occurred, we 
have analysed the dynamics of several endogenous fluorophores across the study period. 
The study of individual fluorophores is not well suited to this type of spectroscopy, as day 
to day variations in both laser power and tissue condition can affect amplitudes of 
fluorescence. We therefore found no consistent patterns of fluorescence from individual 
fluorophores. Instead, we looked at ratios of particular fluorophores relative to one 
another. The measurement of ratios, as used previously by Georgakoudi [7], Ostrander 
[13] and ourselves [11], among others, provides a much more robust measurement of 
fluorescence dynamics. In particular, we focussed on the metabolic cofactors NADH and 
flavins, and the structural protein elastin, all known to fluoresce under UV excitation. As 
the source of NADH and flavins is primarily cellular, our conclusion is that the 
progressive decrease in ratios of elastin/NADH and elastin/flavins may reflect adherence, 
epithelialisation and invasion of tissue by cancer cells. Furthermore, it may also directly 
reflect the progressive destruction of the structural protein elastin in the surrounding 
connective tissue of the mucosa, lamina propria and muscular layers as cancer cells attach 
and begin to secrete digestive enzymes such as matrix metalloproteinases to promote 
invasion. We know from previous studies that the urothelium (2-3 cells thick) contributes 
significantly to the NADH and flavin signals present in bladder tissue. In optical biopsies 
obtained by multi-photon microscopy, intense autofluorescence can be observed on the 
top layers of urothelium with strong second harmonic generation (SHG) signal from 
collagen observed below [26]. We consider that the main fluorophores contributing to 
organoid fluorescence may be NADH and flavins from the new tumour urothelium, while 
control fluorescence may contain a higher contribution from the underlying collagen and 
elastin matrix of the lamina propria and extra-cellular matrix (ECM). Previous studies 
have suggested increased optical redox ratios (increased NADH relative to flavins) in 
cancer cells and tumours compared to healthy controls [11]. We see the opposite of this – 
a reduced optical redox ratio in the tumour organoid. This could be a result of changes in 
structural proteins, rather than changes in metabolism. As the excitation and emission 
profiles of elastin overlap somewhat with that of NADH, the complex fluorescence 
spectrum arising from UV excited tissue likely contains an NADH signal at 490nm with 
underlying contribution from elastin. The epithelialisation of organoids results in 
increased cellular fluorophores, therefore the reduced ORR seen in organoids may be a 
function of the increased Flavin to elastin ratio we observe rather than a reduced NADH – 
flavin couple. We suggest from this research that studying the relative changes in elastin 
and collagen compared to NADH and flavins may serve as a useful tool for monitoring 
bladder tumour development. In this work, we have demonstrated a method for studying 
the dynamic changes in fluorophore levels during colonisation and invasion of bladder 
tissue by tumour cells. That cells were still viable by day 21 of the study suggests this 
model could be further used for evaluation of fluorescent responses to drug and treatment 
regimens such as Mitomycin C, akin to microscopy work done by Walsh et al. for breast 
cancer [27]. Moving forward, it would also be interesting to study the fluorescence 
dynamics of colonisation of scaffolds by cell lines representing different grades of urinary 
bladder cancer. We could then identify, using fluorescence spectroscopy, critical time 
points where fluorescence differs, giving a clinical insight into spectral cues for 
malignancy and invasion in bladder cancer. The application of multi-photon and second 
harmonic generation (SHG) imaging to the study of these organoids may allow us to 
develop a better understanding of cellular and structural behaviour. Finally, information 
gleaned on the fluorescence dynamics of developing tumour in vitro may allow us to 
inform and develop currently used methodologies of computer simulation and modelling 
of the disease [28]. 
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